‘Nutrition almost acts like a TB vaccine’
Nowhere near the 2025 tuberculosis elimination goal, India in July roped in Soumya Swaminathan as principal adviser to the National Tuberculosis Elimination Programme. The former Chief Scientist at WHO and Director General of ICMR talks to Aditi Tandon about the challenges in the fight against TB. Key Points
The TribuneWHO approves Hyderabad firm's new oral polio vaccine for immunisation
The World Health Organisation has approved a new Oral Polio vaccine type 2 (nOPV2) from Hyderabad-based Biological E. Limited, marking a significant step in the fight against polio. Key Points
India TodayNew nasal Covid-19 vaccine trial kicks off in US
A Phase 1 trial to test an experimental nasal vaccine designed to protect against emerging SARS-CoV-2 variants has begun. The trial is currently enrolling healthy adults at multiple locations across the United States. Key Points
India TodayThere’s New Hope for an HIV Vaccine
A trial vaccine has succeeded in generating low levels of antibodies needed to target HIV. It’s a first but much-needed step toward preventing infection. Key Points
WIREDExplainer: Why has AstraZeneca recalled Covid-19 vaccine
Company’s Covid vaccine is sold as Covishield in India and Vaxzevria in Europe. In a significant move, pharma giant AstraZeneca has recalled its Covid-19... Key Points
The Tribune India
Good shot, bad shot: What you need to know about Covishield issue
Covishield Side Effects: Controversies surrounding vaccine side-effects persist despite Covid-19 waning. Covishield, developed by AstraZeneca and Oxford University, faces scrutiny in India following reports of rare side effects. Legal battles and demands for compensation have emerged as families of alleged victims seek justice. Experts stress the importance of understanding risks versus benefits in vaccine administration. Key Points
Economic TimesBharat Biotech starts clinical trials of TB jab
The only vaccine in use today--BCG (Bacillus Calmette and Guerin)--is an attenuated variant of the bovine TB pathogen. This is more than a hundred years old and has a limited effect on pulmonary tuberculosis, which is mostly responsible for the transmission of the disease. Studying the safety, immunogenicity and efficacy of MTBVAC in the most populated country in the world and the one with the highest number of cases of this infectious disease is key to continue advancing in this vaccine, the company said. Key Points
Economic TimesBharat Biotech begins clinical trials of TB vaccine on adults in India
Bharat Biotech International Ltd has initiated clinical trials for the Tuberculosis vaccine Mtbvac on adults in India. Developed by the Spanish biopharmaceutical company Biofabri, Mtbvac is the first TB vaccine derived from a human source. The vaccine aims to be more effective and longer-lasting than the current BCG vaccine for newborns and to prevent TB in adults and adolescents, for whom there is currently no effective vaccine. The trials are a significant step, especially in a country like India where 28% of the world's TB cases occur. Key Points
Economic TimesAll about two rare Covid-19 vaccine side effects detected in a study
Two new extremely rare side effects of Covid-19 vaccine have been uncovered by a recent study. Here's all you want to know. | Health Key Points
Hindustan TimesModerna’s mRNA vax shows promise against virus that causes birth defects
The vaccine also effectively triggers the immune system to destroy cytomegalovirus-infected cells. An experimental mRNA vaccine by US-drug maker Moderna... Key Points
The Tribune India
British Punjabi doctor leads ground-breaking international trial of bowel cancer vaccine
Other News News: A British Punjabi doctor is leading a ground-breaking international trial of a landmark vaccine to fight bowel cancer. The vaccine, designed by Imugene, will be tested on 44 patients across the UK and Australia. This trial could be a major breakthrough in bowel cancer treatment. Key Points
Times Of IndiaIIL rolls out India’s 1st indigenous Hepatitis-A vax Havisure
India Business News: Indian Immunologicals Ltd (IIL) has rolled out Havisure, India's first indigenous Hepatitis-A vaccine. The vaccine, developed over eight years, is aimed at protecting against the highly contagious liver infection transmitted through contaminated food or water. The two-dose vaccine is suitable for pediatric, adolescent, and adult use. It has undergone extensive clinical trials and has been proven safe and efficacious. The vaccine is priced at Rs 2,150 per dose. IIL has a manufacturing capacity of 1 million doses per year. Havisure is the third vaccine rolled out by IIL in a year's time. Key Points
Times Of IndiaBiological E's Covid-19 vaccine CORBEVAX gets WHO emergency use listing
India Business News: Biological E's Covid-19 vaccine CORBEVAX has received emergency use listing from the World Health Organisation (WHO). The vaccine was approved in India for restricted use in emergency for adults, adolescents, and young children, as well as a heterologous booster dose for those aged 18 years and above. The Hyderabad-based vaccine maker has already supplied 100 million doses of CORBEVAX to the Indian government. The WHO EUL will help the company continue developing Covid-19 vaccines. Key Points
Times Of IndiaHuman testing of first Nipah virus vaccine begins
The first participants in the Oxford trial received doses of the vaccine over the last week. The shot is based on the same technology as the one used in AstraZeneca (AZN.L) and Serum Institute of India's Covid-19 shots. Key Points
India TodayThe Long Quest for a Universal Flu vaccine Finally Takes Its First Steps
The search for a shot that could protect us against many strains—and maybe a pandemic—is notching achievements at last. But the flu’s endless mutation and our own biology stand in the way. Key Points
WIRED.jpg)
Katalin Karikó’s Nobel Prize Marks the Beginning of an mRNA vaccine Revolution
Nobel Prize winners Katalin Karikó and Drew Weissman pioneered the technology that produced a Covid-19 vaccine in record time. Next, mRNA could tackle flu, malaria, and HIV. Key Points
WIREDNew Malaria Vaccines Offer a Real Shot at Fighting the Disease
A malaria vaccine that could protect millions of children against the parasite-borne disease is expected to roll out early next year. It follows another formula that has already had moderate success. Key Points
WIREDThis vaccine Protects Against Cancer—but Not Enough Boys Are Getting It
The HPV vaccine can effectively prevent a range of cancers if administered at the right age. But boys still can't access it in most countries. Key Points
WIREDNew Malaria Vaccines Offer a Real Shot at Fighting the Disease
A malaria vaccine that could protect millions of children against the parasite-borne disease is expected to roll out early next year. It follows another formula that has already had moderate success. Key Points
WIREDPM Narendra Modi congratulates Vivek Agnihotri for The vaccine War
The vaccine War is directed by Vivek Agnihotri. It has Nana Patekar, Sapthami Gowda, Pallavi Joshi, Raima Sen and Anupam Kher. | Bollywood Key Points
Hindustan TimesNovavax: The new FDA-approved COVID-19 vaccine with fewer side effects
The FDA approved an updated COVID-19 vaccine from Novavax. The vaccine is more effective at protecting against omicron strains of the virus. Key Points
InsiderRicha Chadha, Pankaj Tripathi, Pulkit Sharma’s Fukrey 3 Vs Vivek Agnihotri’s The vaccine War | Explained
'The vaccine War', starring Nana Patekar and Pallavi Joshi in the lead roles, had a terrible run in its initial days at the box office. On the other hand, Pulkit Sharma’s Fukrey did way better at the box office. Key Points
FirstpostKatalin Karikó’s Nobel Prize Marks the Beginning of a vaccine Revolution
Nobel Prize winners Katalin Karikó and Drew Weissman pioneered the technology that produced a Covid-19 vaccine in record time. Next, mRNA could tackle flu, malaria, and HIV. Key Points
WIREDUN authorises 2nd malaria vaccine, developed by Oxford University with help from Serum Institute of India
Research suggests it is more than 75% effective and that protection is maintained for at least another year with a booster. Tedros said the shot would cost about $2 to $4 and could be available in some countries next year. Key Points
Economic TimesThe vaccine War box office: Vivek Agnihotri film earns ₹3.2 crore in 3 days
The vaccine War box office collection day 3: The film hasn't been doing well in India. It stars Nana Patekar, Pallavi Joshi, Raima Sen and Anupam Kher. | Bollywood Key Points
Hindustan Times
The vaccine War box office collection day 2: Vivek Agnihotri film mints ₹85 lakh
The vaccine War box office collection day 2: The film earned ₹1.50 crore in two days since its release. It stars Nana Patekar, Anupam Kher and Pallavi Joshi. | Bollywood Key Points
Hindustan TimesThe vaccine War box office collection: Vivek Agnihotri film has low opening
The vaccine War box office collection: The Nana Patekar and Pallavi Joshi-starrer was released on Thursday, and earned ₹1.3 crore. | Bollywood Key Points
Hindustan TimesVivek Agnihotri’s The vaccine War Movie Review
Vivek Agnihotri’s film stars Nana Patekar, Pallavi Joshi and Raima Sen. The vaccine War tells the story of India and how the scientists fought against the virus. Key Points
FirstpostMadhavan calls Vivek Agnihotri master storyteller after watching The vaccine War
The vaccine War stars Anupam Kher, Raima Sen and Pallavi Joshi in the lead roles. The film is all set to hit the theatres on September 28. | Bollywood Key Points
Hindustan TimesNovavax to receive $350 mln from Canada for unused COVID shots
Novavax Inc (NVAX.O) said on Friday Canada will pay $349.6 million to settle the forfeiting of certain doses of its COVID-19 vaccine previously scheduled for delivery. Key Points
Reuters/cloudfront-us-east-2.images.arcpublishing.com/reuters/T6XMIEWQSRPB5JU6OLU255TQSE.jpg)
Almost $1.9 billion left in COVID vaccine scheme for future health efforts -Germany
Almost $1.9 billion left in the global scheme to share COVID-19 vaccines more equitably will be used to help prepare for future pandemics and other health threats, said the German development ministry on Tuesday. Key Points
ReutersIndia’s first mRNA-based Omicron-specific booster vaccine from Pune-based Gennova gets DCGI approval
Gennova Biopharmaceuticals' mRNA Covid-19 booster vaccine, 'Gemcovac Om', has received emergency use authorisation from the office of the Drugs Controller General of India for the Omicron variant. The vaccine is the first booster Covid-19 vaccine developed in India against the highly transmissible Omicron variant and has demonstrated robust immune responses in phase 3 clinical trials. It is stable at two to eight degrees Centigrade and has been developed using Gennova's indigenous platform technology, supported under 'Mission Covid Suraksha'. Key Points
Hindustan TimesFirst Omicron-specific mRNA vaccine from India approved by regulators
India’s first indigenous mRNA vaccine for the Omicron variant, GEMCOVAC-OM, developed by Pune-based Gennova Biopharmaceuticals Ltd, was approved under emergency use guidelines by the Drug Controller General of India late on June 19. This comes a year after the company got approval for GEMCOVAC-19, the country’s first m-RNA vaccine against COVID-19. Key Points
The HinduOne-shot chikungunya vaccine found safe, effective in first phase 3 trial: Lancet study
After a single vaccination, VLA1553 induced antibody levels at a level that is considered to protect against disease among 99 per cent (263/266) of participants. There was no difference in immune response according to age, the researchers said. Key Points
The Indian ExpressInternational cooperation essential for vaccine development of emerging pathogens: Health Minister
Health Minister Dr. Mansukh Mandaviya on June 3 said “international cooperation is essential to advance vaccine development for emerging pathogens, and the G20 can serve as a vital platform to facilitate collaboration between governments, research organisations, pharmaceutical companies, and other stakeholders.” Key Points
The Hindu/cloudfront-us-east-2.images.arcpublishing.com/reuters/5AW6TXSZZRMSTHQRSGPBZ33NNU.jpg)
Moderna reports surprise profit as it books deferred COVID vaccine sales
Moderna Inc on Thursday reported a small profit of 19 cents per share instead of an expected loss as it booked more revenue in the first quarter from last year's deferred orders for its COVID-19 vaccine than had been anticipated. Analysts expected a loss of $1.77 per share, according to Refinitiv data, and Moderna shares had jumped more than 5% to $136.71 by midday. They had fallen nearly 28% this year. Key Points
ReutersAmid Covid surge, Tricity short of vaccine doses
Since April 1, residents of Chandigarh have been unable to receive the Covid-19 vaccine as stock ended by March 31. The local health department has reached out to the Government of India for additional vaccine supplies, but there is currently no information on when the fresh stock will arrive. Key Points
Hindustan TimesCash-strapped biotech firm Codiak files for bankruptcy protection
Codiak BioSciences Inc said on Monday it has filed for U.S. bankruptcy protection in the latest blow to the struggling drug developer's ambitions of making a COVID-19 vaccine. Key Points
ReutersManoj Bajpayee: 'Covid-19 was like a Tsunami that could've wiped out human species completely'
History TV18 has launched a documentary called The Vial: India’s vaccine Story that will stream on the channel on March 24 at 8 pm. It’s nearly an hour long and narrated by Manoj Bajpayee. Key Points
Firstpost